The Readout Loud 333: An H5N1 bird flu update and talent scarcity in the radiopharma field
8 snips
Dec 5, 2024 Helen Branswell, STAT’s infectious disease reporter, gives an urgent update on the ongoing H5N1 bird flu outbreak, highlighting a concerning rise in human cases and potential mutation risks. The discussion also covers key findings from a recent weight loss medication showdown between Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy. Additionally, there's a deep dive into the talent shortage in the radiopharmaceutical industry, detailing the struggle to attract skilled professionals and the impact on cancer treatment innovations.
AI Snips
Chapters
Transcript
Episode notes
Zepbound Outperforms Wegovy
- Eli Lilly's Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head obesity drug study.
- Zepbound users lost significantly more weight, potentially impacting Lilly's marketing.
Amgen's AMG 133 Shows Promise
- Amgen's obesity drug, AMG 133, showed promising weight loss in a Phase 2 study.
- The drug's potential monthly dosing could give it a competitive edge, despite some debate about side effects.
Talent Shortage in Radiopharma
- Radiopharmaceuticals, a new class of cancer drugs, face a talent shortage.
- Companies struggle to find and retain employees with the specialized knowledge to develop and administer these drugs.